Key Takeaways:
ImmunityBio Inc. (NASDAQ: IBRX) secured exclusive U.S. rights to a second source of a critical bladder cancer therapy, positioning the company to address a drug shortage that has challenged American urologists for more than a decade. The agreement with Japan BCG Laboratory (JBL) provides ImmunityBio with the Tokyo-172 strain of Bacillus Calmette-Guérin (BCG), a foundational treatment for non-muscle invasive bladder cancer (NMIBC).
“U.S. urologists and their patients have lived with a chronic BCG shortage for more than a decade,” said Richard Adcock, President and Chief Executive Officer of ImmunityBio. “This agreement with Japan BCG Laboratory for the Tokyo strain of BCG gives ImmunityBio a second potential BCG source for the United States. We plan to work with the FDA on the regulatory path for the Tokyo strain of BCG.”
The deal is supported by strong clinical data from a large-scale, government-sponsored study. The National Cancer Institute-sponsored SWOG S1602 Phase III trial, which enrolled 984 patients, demonstrated that the Tokyo strain was non-inferior to the TICE strain of BCG, the current standard. The trial reported a hazard ratio of 0.82 for high-grade recurrence-free survival, with an estimated 5-year survival rate of 64 percent in the Tokyo arm versus 58 percent in the TICE arm.
This agreement is a key strategic move for ImmunityBio, whose stock has surged over 283 percent in the past six months. By securing a new BCG source, the company not only creates a potential new revenue stream but also shores up the supply chain for its FDA-approved drug ANKTIVA, which is administered in combination with BCG for patients with BCG-unresponsive NMIBC.
The data backing the Tokyo strain comes from a rigorous, multi-year clinical trial. The SWOG S1602 study showed that after a median follow-up of 4.6 years, the Tokyo-172 BCG was statistically as effective as the TICE BCG strain. The primary endpoint of high-grade recurrence-free survival had a hazard ratio of 0.82, with the 95.8% confidence interval (0.63–1.08) falling well below the pre-specified non-inferiority margin of 1.34.
Progression-free survival was similar between the two arms. The complete response rate for carcinoma in situ (CIS), an early-form of bladder cancer, was 66.4 percent for the Tokyo strain at six months, compared to 70.2 percent for the TICE strain. ImmunityBio is now in discussions to use this data for a Biologics License Application (BLA) with the U.S. Food and Drug Administration.
The agreement with Japan BCG Laboratory is ImmunityBio's second major partnership aimed at solving the BCG shortage. The company already works with the Serum Institute of India, one of the world's largest vaccine makers, to supply a recombinant BCG (rBCG) through an FDA Expanded Access Program.
Together, these two sources could create a more reliable supply for American patients. The Tokyo strain has been used for almost 30 years in Japan to treat high-risk NMIBC, but it remains an investigational product in the United States. ImmunityBio will now lead the effort for U.S. approval, serving as the sole BLA applicant and eventual Marketing Authorization Holder. This move solidifies the company's central role in the bladder cancer treatment landscape, complementing its existing immunotherapy platform.
This article is for informational purposes only and does not constitute investment advice.
